Table 2.
Correlation analysis between the LSAMP-AS1 expression and the clinicopathological characteristics of PCa patients.
| Characteristics | N (%) | LSAMP-AS1 expression | p value |
|---|---|---|---|
| Age (year) | 0.6253 | ||
| ≤ 65 | 41 (46.59) | 0.41 ± 0.09 | |
| > 65 | 47 (53.41) | 0.40 ± 0.10 | |
| Gleason grade | 0.0104 | ||
| ≤ 6 | 47 (53.41) | 0.43 ± 0.08 | |
| 3 + 4 | 6 (6.82) | 0.39 ± 0.07 | |
| 4 + 3 | 8 (9.09) | 0.41 ± 0.11 | |
| 8 | 11 (12.50) | 0.38 ± 0.08 | |
| 9 - 10 | 16 (18.18) | 0.34 ± 0.10 | |
| PSA (ng/mL) | 0.6082 | ||
| ≤ 10 | 37 (42.05) | 0.41 ± 0.09 | |
| > 10 | 51 (57.95) | 0.40 ± 0.10 | |
| TNM staging | 0.0026 | ||
| I – II stage | 49 (55.68) | 0.43 ± 0.09 | |
| III – IV stage | 39 (44.32) | 0.37 ± 0.09 | |
| Risk stratification | 0.0080 | ||
| Low risk | 38 (43.18) | 0.44 ± 0.08 | |
| Intermediate risk | 10 (11.36) | 0.39 ± 0.08 | |
| High risk | 40 (45.45) | 0.38 ± 0.09 |
Note: PSA, prostate specific antigen; TNM, tumor node metastasis; Data were measurement data, expressed by means ± standard deviation. Comparison between two groups was analyzed by independent-sample t-test. Comparison among multiple groups was analyzed by one-way ANOVA, followed by a Tukey's post hoc test.